Overview
The purpose of this study is to evaluate tirzepatide within a real-world setting to assess body weight loss and incidence of type 2 diabetes in adults without diabetes who have obesity and at least one weight-related comorbid condition. Participation in the study will last about 260 weeks.
Eligibility
Inclusion Criteria:
- Have a body mass index ≥30 and ≤34.9 kilogram per square meter (kg/m2)
- Have an increased waist to height ratio (defined by \>0.5)
- Have at least one weight related comorbid condition
- Have had at least one attempt to lose weight with lifestyle intervention (diet and physical activity)
Exclusion Criteria:
- Have type 1 diabetes, type 2 diabetes, or any other types of diabetes
- Have had a change in body weight of greater than 5 kilograms (11 pounds) within 90 days prior to screening